Conversations about cannabis and cancer are everywhere, from news stories to social media. For some, cannabis represents hope, for others, confusion. What’s clear is that research is still catching up with public interest.
So, what do we actually know about cannabis, its components, and its potential role in cancer care?
What is cannabis?
Cannabis is a plant that has been used for thousands of years, both recreationally and medicinally. The resin it produces contains cannabinoids, chemical compounds that can interact with the human body.
Two of the main cannabinoids are:
- Delta-9-tetrahydrocannabinol (THC) - the compound that causes a “high.”
- Cannabidiol (CBD) - which doesn’t cause a high and is legal in the UK when sold without THC.
The human body naturally produces its own cannabinoids, known as endocannabinoids, which help regulate processes such as appetite, mood and pain. This system is complex and continues to be studied, including how it may relate to certain diseases, cancer among them.
The legal status in the UK
Cannabis remains a Class B drug under UK law, meaning it’s illegal to possess or supply it. However, several prescribed medicines derived from cannabis are approved for use in the NHS, including:
- Nabilone, used to help control nausea and vomiting caused by chemotherapy.
- Epidyolex, used to treat certain types of severe epilepsy.
These are highly regulated medicines, prescribed only when other treatments haven’t worked.
CBD products, such as oils, drops, or gummies, are legal to buy in the UK if they contain no THC and are marketed as food supplements. They cannot legally claim to treat or prevent disease.
What about cannabis oil?
Cannabis oil products vary widely. Some contain only CBD, while others, often sold illegally, include THC. Pure CBD oil is legal to buy as a food supplement in the UK, but products sold online or in shops are not medicines and are not regulated for quality or content.
People living with cancer sometimes explore CBD oil to help with pain, anxiety or sleep. However, claims that CBD or cannabis oil can cure or shrink cancer are not supported by scientific evidence.
If a patient wishes to try CBD, they should always speak to their GP, pharmacist or cancer care team first - especially as CBD can interact with other prescribed medicines.
Cannabis and cancer: what the evidence shows
Researchers around the world have been studying cannabinoids and their potential role in cancer treatment. The results have been mixed and mostly early stage.
Some laboratory studies show that cannabinoids can:
- Trigger cancer cells to die (a process called apoptosis).
- Slow the growth of certain cancer cells.
- Prevent tumours from forming new blood vessels.
However, other studies have found that cannabinoids can:
- Damage healthy blood vessels.
- Sometimes promote cancer cell growth under certain conditions.
It’s also important to note that most of this research has been done in cells in the lab or in animals, not in people. What works in a petri dish doesn’t always translate into safe or effective treatments for patients.
As of 2025, there is no reliable clinical evidence that cannabis or cannabinoids can treat or cure cancer in humans.
What the research is exploring
Recent trials are beginning to look at cannabinoids in controlled, medical settings. These studies focus mainly on symptom control or exploring whether cannabinoids can be safely combined with standard treatment - not on replacing proven therapies.
Medicinal cannabis for symptom control in advanced cancer (2025)
A randomised, double-blind clinical trial tested a cannabis oil against placebo in patients with advanced cancer. The trial found no difference in overall symptom distress, though some patients reported a small reduction in pain. However, this came with higher rates of side effects such as dizziness and fatigue, highlighting the need for further research into safe dosing.
(Hardy et al., 2025).
The ARISTOCRAT trial – UK, ongoing
The ARISTOCRAT trial, led by the University of Leeds and the University of Birmingham, is testing nabiximols (Sativex), a balanced THC:CBD oral spray, alongside standard chemotherapy for people with recurrent glioblastoma. Early data suggests the treatment is well tolerated. The study aims to understand whether adding cannabinoids could improve survival.
(University of Leeds, 2021; The Brain Tumour Charity, 2023; BMC Cancer trial protocol, University of Birmingham, 2023)
Together, these studies show that research is progressing, but there is still no clear evidence that cannabinoids improve cancer outcomes.
What we still need to understand
There are still important questions to answer:
- Which cannabinoids (natural or synthetic) might be most effective?
- What doses are safe and meaningful?
- Which cancer types, if any, might respond?
- How do cannabinoids interact with existing treatments like chemotherapy or immunotherapy?
Until large, well-controlled clinical trials can answer these questions, cannabis cannot be recommended as a cancer treatment.
The bottom line
There’s currently no reliable evidence that cannabis or cannabis oil can treat or cure cancer.
Some cannabinoids may help manage symptoms such as pain, sickness or appetite loss, but always under clinical supervision.
For anyone considering CBD or cannabis-based products, the safest step is to talk to a GP or oncology specialist first. They can help review what’s evidence-based, what’s safe, and what may interfere with ongoing treatment.
Because every informed choice, and every early conversation,gives patients back control, confidence and clarity.
References
Hardy JR, Greer RM, Pelecanos A, et al. (2025). Medicinal cannabis for symptom control in advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of 1:1 tetrahydrocannabinol and cannabidiol. Supportive Care in Cancer. DOI: 10.1007/s00520-025-09763-5
University of Leeds (2021). World-first trial tests cannabis-based drug on aggressive brain tumours. Leeds.ac.uk
The Brain Tumour Charity (2023). ARISTOCRAT: a pioneering trial using a cannabinoid-based drug to treat brain tumours. thebraintumourcharity.org
University of Birmingham (2023). A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT). BMC Cancer protocol. birmingham.ac.uk
Cancer Research UK (2023). Cannabinoids and cancer: what we know. news.cancerresearchuk.org